Highlights
• Dual TIGIT and PD‑1 blockade with domvanalimab and zimberelimab added to FOLFOX produced a confirmed objective response rate (ORR) of 59% in previously untreated HER2‑negative advanced gastric, gastroesophageal junction (GEJ) or esophageal adenocarcinoma (n=41).
• Median progression‑free survival (PFS) was 12.9 months and median overall survival (OS) was 26.7 months in the study cohort; responses were higher among PD‑L1–positive tumors.
